We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.'s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. 5 Countries With Highest Rates of AIDS BlurryMe/Shutterstock.com Gilead Sciences (GILD), historically a leader in HIV and hepatitis C treatments, is now positioning onco ...